Nihon Kohden (NHNKY) to Release Earnings on Wednesday
by Mitch Edgeman · The Markets DailyNihon Kohden (OTCMKTS:NHNKY – Get Free Report) is expected to be announcing its resultson Wednesday, August 5th. Analysts expect the company to post earnings of $0.06 per share and revenue of $299.9750 million for the quarter.
Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.10. The business had revenue of $453.10 million for the quarter, compared to analysts’ expectations of $414.40 million. Nihon Kohden had a return on equity of 9.46% and a net margin of 6.08%. On average, analysts expect Nihon Kohden to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Nihon Kohden Stock Up 1.6%
Nihon Kohden stock opened at $9.86 on Wednesday. Nihon Kohden has a 52-week low of $8.12 and a 52-week high of $14.21. The company has a market cap of $1.66 billion, a P/E ratio of 16.71 and a beta of 0.39. The business has a 50-day simple moving average of $9.04 and a two-hundred day simple moving average of $9.85.
Wall Street Analyst Weigh In
Separately, Zacks Research raised shares of Nihon Kohden to a “hold” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Nihon Kohden has an average rating of “Buy”.
Get Our Latest Analysis on NHNKY
About Nihon Kohden
Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.
The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.
Further Reading
- Five stocks we like better than Nihon Kohden
- UPS Just Gave Investors a Second Chance to Buy
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
- D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory
- Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting